Stryker Co. (NYSE:SYK) Shares Sold by Net Worth Advisory Group

Net Worth Advisory Group cut its position in Stryker Co. (NYSE:SYK) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,552 shares of the medical technology company’s stock after selling 29 shares during the period. Net Worth Advisory Group’s holdings in Stryker were worth $559,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Davis R M Inc. increased its holdings in shares of Stryker by 7.3% in the fourth quarter. Davis R M Inc. now owns 133,017 shares of the medical technology company’s stock valued at $47,893,000 after purchasing an additional 9,057 shares during the period. Independent Advisor Alliance boosted its stake in shares of Stryker by 19.4% in the fourth quarter. Independent Advisor Alliance now owns 8,149 shares of the medical technology company’s stock worth $2,934,000 after buying an additional 1,325 shares during the last quarter. Paragon Private Wealth Management LLC boosted its stake in shares of Stryker by 12.6% in the fourth quarter. Paragon Private Wealth Management LLC now owns 1,258 shares of the medical technology company’s stock worth $453,000 after buying an additional 141 shares during the last quarter. Johnson Investment Counsel Inc. boosted its stake in shares of Stryker by 6.5% in the fourth quarter. Johnson Investment Counsel Inc. now owns 176,956 shares of the medical technology company’s stock worth $63,713,000 after buying an additional 10,856 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Stryker by 5.9% in the fourth quarter. Daiwa Securities Group Inc. now owns 51,886 shares of the medical technology company’s stock worth $18,682,000 after buying an additional 2,883 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of Stryker stock opened at $369.16 on Tuesday. The business has a 50 day simple moving average of $382.59 and a two-hundred day simple moving average of $373.31. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a market capitalization of $140.87 billion, a P/E ratio of 47.57, a PEG ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the company earned $3.46 earnings per share. As a group, analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.91%. Stryker’s dividend payout ratio is presently 43.30%.

Wall Street Analyst Weigh In

SYK has been the topic of a number of recent research reports. Needham & Company LLC restated a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. Truist Financial upped their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. Royal Bank of Canada upped their target price on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Argus set a $450.00 target price on Stryker in a research note on Monday, February 3rd. Finally, StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.